(2-Chlorphenyl)-propylketon | 21550-07-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (2-Chlorphenyl)-propylketon
• 英文别名: o-Chlor-butyrophenon；1-(2-Chlorophenyl)butan-1-one
• CAS: 21550-07-2
• 化学式: C₁₀H₁₁ClO
• 分子量: 182.65
• InChiKey: FDPBBAUOCMWIAO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (2-Chlorphenyl)-propylketon 在 盐酸羟胺 、 sodium acetate 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 5.0h， 生成 1-(2-chlorophenyl)butan-1-one O-acetyl oxime
  参考文献：
  名称：

  Copper‐Catalyzed Aza‐Sonogashira Cross‐Coupling To Form Ynimines: Development and Application to the Synthesis of Heterocycles

  摘要：

  AbstractNitrogen‐substituted alkynes, such as ynamines and ynamides, are versatile synthetic building blocks. Ynimines bearing additional nucleophilic and electrophilic centers relative to ynamines and ynamides are expected to have high synthetic potential. However, their chemical reactivity remains unexplored owing mainly to the lack of synthetic accessibility. We report herein a versatile copper‐catalyzed synthesis of ynimines from readily available O‐acetyl ketoximes and terminal alkynes. A wide range of O‐acetyl ketoximes derived from diaryl ketones, aryl alkyl ketones and dialkyl ketones underwent cross‐coupling with a diverse set of terminal alkynes to afford the ynimines in good to excellent yields. An unprecedented [5+1] heteroannulation reaction exploiting the reactivity of the ynimine generated in situ was subsequently developed for the synthesis of medicinally important heterocycles, including isoquinolines, azaindoles, azabenzofurans, azabenzothiophenes and carbolines.

  DOI：

  10.1002/anie.202110901

文献信息

• Substituted heterocycle fused gamma-carbolines
  申请人：——

  公开号：US20040220178A1

  公开（公告）日：2004-11-04

  The present invention is directed to methods of treating addictive behavior and sleep disorders by administering compounds represented by structural Formula (I) 1 or pharmaceutically acceptable salt forms thereof, wherein R 1 , R 5 , R 6a , R 6b , R 7 , R 8 , R 9 , X, b, k, m, and n, and the dashed lines are described herein. The compounds used in the method of treatment of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including addictive behavior and sleep disorders.

  本发明涉及通过给予由结构式（I）表示的化合物或其药学上可接受的盐形式来治疗成瘾行为和睡眠障碍的方法，其中R1、R5、R6a、R6b、R7、R8、R9、X、b、k、m和n以及虚线如本文所述。本发明治疗方法中使用的化合物是5-羟色胺激动剂和拮抗剂，对于控制或预防包括成瘾行为和睡眠障碍在内的中枢神经系统疾病是有用的。
• PROTEIN CROSSLINKING INHIBITOR AND USE OF THE SAME
  申请人：Mikoshiba Katsuhiko

  公开号：US20120277423A1

  公开（公告）日：2012-11-01

  The present invention relates to: a ketone compound having transglutaminase-inhibiting activity, which is represented by the following Formula 1, 2, or 3: wherein R 1 is a substituted or unsubstituted aryl or heterocyclyl group, R 2 , R 3 , and R 4 are hydrogen atoms, n is 2, X is halogen, R 5 and R 6 independently represent a hydrogen atom or a substituted or unsubstituted C1-C10 alkyl, aryl, or aralkyl group, wherein R 5 and R 6 are not hydrogen atoms at the same time, or R 5 and R 6 may be taken together to form a saturated or unsaturated and substituted or unsubstituted heterocyclyl group containing a nitrogen atom (N); an inhibitor of protein crosslinking comprising the compound; and a composition for preventing or treating a protein-crosslinking causative disease, which comprises the compound or the protein crosslinking inhibitor.

  本发明涉及：一种具有转谷氨酰胺酶抑制活性的酮化合物，由下式1、2或3表示： 其中R1是取代或未取代的芳基或杂环基团，R2、R3和R4是氢原子，n是2，X是卤素，R5和R6独立地表示氢原子或取代或未取代的C1-C10烷基、芳基或芳烷基团，其中R5和R6不同时为氢原子，或者R5和R6可以共同形成含氮原子（N）的饱和或未饱和的、取代或未取代的杂环基团；包含该化合物的蛋白质交联抑制剂；以及包含该化合物或蛋白质交联抑制剂的用于预防或治疗由蛋白质交联引起的疾病的组合物。
• Structure-based design of potent human dihydroorotate dehydrogenase inhibitors as anticancer agents
  作者：Wenlin Song、Shiliang Li、Yi Tong、Jiawei Wang、Lina Quan、Zhuo Chen、Zhenjiang Zhao、Yufang Xu、Lili Zhu、Xuhong Qian、Honglin Li

  DOI：10.1039/c6md00179c

  日期：——

  promising target for the treatment of immunological disease and cancer. Here, a succession of substituted hydrazino-thiazole derivatives were designed, synthesized, and biologically evaluated through structure-based optimization, of which compound 22 was the most potent inhibitor of hDHODH with an IC50 value of 1.8 nM. Furthermore, 22 exhibited much better antiproliferative activity than brequinar, both

  已经证明抑制人二氢乳清酸脱氢酶（h DHODH）会限制快速增殖的细胞的生长，因此h DHODH可作为治疗免疫性疾病和癌症的有希望的靶标。在这里，通过基于结构的优化设计，合成了一系列取代的肼基噻唑衍生物，并对其进行了生物学评估，其中化合物22是h DHODH的最有效抑制剂，IC 50值为1.8 nM。此外，在HCT-116和BxPC-3癌细胞系中，有22种抗增殖活性均优于溴喹。流式细胞仪分析发现22诱导S期细胞周期停滞并促进凋亡诱导。所有结果证实了通过抑制限速酶h DHODH阻断嘧啶从头合成途径是一种有吸引力的癌症治疗方法。
• Process for the preparation of 1-[4-(1,1-dimethylethyl)phenyl]-4-[4-(diphenylmethoxy)-1-piperidinyl]-1-butanone and acid addition salts thereof
  申请人：Arevipharma GmbH

  公开号：EP2371817A1

  公开（公告）日：2011-10-05

  The present invention describes processes for the preparation of 1-[4-(1,1-dimethylethyl)phenyl]-4-[4-(diphenylmethoxy)-1-piperidinyl]-1-butanone and acid addition salts thereof.

  该发明描述了制备1-[4-(1,1-二甲基乙基)苯基]-4-[4-(二苯甲氧基)-1-哌啶基]-1-丁酮及其酸盐的过程。
• [EN] MONOAMINE REUPTAKE INHIBITORS<br/>[FR] INHIBITEURS DE LA RECAPTURE DES MONOAMINES
  申请人：RES TRIANGLE INST

  公开号：WO2010121022A1

  公开（公告）日：2010-10-21

  The invention provides bupropion analogue compounds capable of inhibiting the reuptake of one or more monoamines. The compounds may selectively bind to one or more monoamine transporters, including those for dopamine, norepinephrine, and serotonin. Such compounds may be used to treat conditions that are responsive to inhibition of the reuptake of monoamines, including addiction, depression, and obesity.

  该发明提供了一种能够抑制一种或多种单胺再摄取的丁丙吡胺类似化合物。这些化合物可以选择性地结合到一种或多种单胺转运体上，包括多巴胺、去甲肾上腺素和5-羟色胺的转运体。这些化合物可用于治疗对单胺再摄取抑制有响应的疾病，包括成瘾、抑郁和肥胖症。